Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Insulin Aspart (NovoLog) vs Insulin Glargine (Lantus)
An educational, source-based comparison of Insulin Aspart (NovoLog) and Insulin Glargine (Lantus) — how each peptide works, what it's researched for, and what to know before going deeper.
Recombinant insulin analog with proline→aspartic acid at B28, reducing hexamer stability for rapid absorption and prandial glucose control.
- Prandial coverage
- CSII pump therapy
- Inpatient glycemic management
- • FDA-approved.
- • Hypoglycemia is the principal risk.
Long-acting basal insulin analog for type 1 and type 2 diabetes.
Recombinant human insulin analog with two arginine residues added to the B-chain and asparagine→glycine at A21, forming microprecipitates at injection site for ~24-hour glucose-lowering activity via insulin receptor activation.
- Type 1 diabetes basal coverage
- Type 2 diabetes basal insulin therapy
- Gestational diabetes
- • FDA-approved.
- • Hypoglycemia and weight gain are primary risks.
- • Do not mix with other insulins.
Insulin Aspart (NovoLog) vs Insulin Glargine (Lantus) — Key differences
- Class: Insulin Aspart (NovoLog) is classified as Insulin Analog · Endocrine, while Insulin Glargine (Lantus) is Insulin Analog · Endocrine.
- Primary research focus: Insulin Aspart (NovoLog) — prandial coverage; Insulin Glargine (Lantus) — type 1 diabetes basal coverage.
- Tag: FDA-Approved · Diabetes vs FDA-Approved · Diabetes.